Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease

    Summary
    EudraCT number
    		 2017-004783-35
    Trial protocol
    		 DE   GB   HU   ES   IT  
    Global end of trial date
    31 Mar 2025

    Results information
    Results version number
    		 v1(current)
    This version publication date
    27 Mar 2026
    First version publication date
    27 Mar 2026
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    OPH2005
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT03364153
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Astellas Pharma Global Development, Inc
    Sponsor organisation address
    1 Astellas Way, Northbrook, United States, 60062
    Public contact
    Clinical Transparency, Astellas Pharma Global Development, Inc, +1 800-888-7704, astellas.resultsdisclosure@astellas.com
    Scientific contact
    Clinical Transparency, Astellas Pharma Global Development, Inc, +1 800-888-7704, astellas.resultsdisclosure@astellas.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    31 Mar 2025
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Mar 2025
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The main objective of this study is to evaluate the safety and efficacy of avacincaptad pegol (ACP) intravitreal injection compared to sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
    Protection of trial subjects
    This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the following: ● Declaration of Helsinki and CIOMS International Ethical Guidelines ● Applicable ICH GCP Guidelines ● Applicable laws and regulations
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    12 Jan 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    France: 2
    Country: Number of subjects enrolled
    Germany: 11
    Country: Number of subjects enrolled
    Hungary: 10
    Country: Number of subjects enrolled
    Israel: 6
    Country: Number of subjects enrolled
    Italy: 19
    Country: Number of subjects enrolled
    Spain: 9
    Country: Number of subjects enrolled
    United Kingdom: 1
    Country: Number of subjects enrolled
    United States: 63
    Worldwide total number of subjects
    121
    EEA total number of subjects
    51
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    121
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Participants of either gender, of 18 to 60 years of age (inclusive), with the diagnosis of autosomal recessive STGD1 were enrolled in this study.

    Pre-assignment
    Screening details
    		 Participants who met all inclusion criteria and none of the exclusion criteria were enrolled in the study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Avacincaptad Pegol
    Arm description
    		 The participants received ACP 2 mg/eye on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: ACP 2 mg/eye o D14: ACP 2 mg/eye And the participants then received ACP 4 mg/eye monthly (Month 3 – Month 17) in the Maintenance Phase.
    Arm type
    		 Experimental

    Investigational medicinal product name
    avacincaptad pegol
    Investigational medicinal product code
    ARC1905
    Other name
    Zimura (previous name) Izervay
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravitreal use
    Dosage and administration details
    Intravitreal Injection

    Arm title
    		 Sham
    Arm description
    		 The participants received Sham on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: Sham o D14: Sham And the participants then received Sham monthly (Month 3 – Month 17) in the Maintenance Phase.
    Arm type
    		 Placebo

    Investigational medicinal product name
    sham
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravitreal use
    Dosage and administration details
    Intravitreal Injection

    Number of subjects in period 1
    		Avacincaptad Pegol Sham
    Started
    61
    60
    Safety Analysis Set (SAF)
    61
    58
    Completed
    44
    53
    Not completed
    17
    7
         Adverse event, serious fatal
    1
    -
         Adverse event, non-fatal
    4
    1
         Other
    2
    1
         Subject request
    7
    3
         Lost to follow-up
    2
    -
         Protocol deviation
    1
    2

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Avacincaptad Pegol
    Reporting group description
    		 The participants received ACP 2 mg/eye on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: ACP 2 mg/eye o D14: ACP 2 mg/eye And the participants then received ACP 4 mg/eye monthly (Month 3 – Month 17) in the Maintenance Phase.

    Reporting group title
    Sham
    Reporting group description
    		 The participants received Sham on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: Sham o D14: Sham And the participants then received Sham monthly (Month 3 – Month 17) in the Maintenance Phase.

    Reporting group values
    		 Avacincaptad Pegol Sham Total
    Number of subjects
    		 61 60 121
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 61 60 121
        From 65-84 years
    		 0 0 0
        85 years and over
    		 0 0 0
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    		 33.8 ( 7.90 ) 36.1 ( 10.58 ) -
    Gender, Male/Female
    Units: Participants
        Female
    		 41 31 72
        Male
    		 20 29 49
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    		 0 0 0
        Asian
    		 3 1 4
        Native Hawaiian or Other Pacific Islander
    		 0 0 0
        Black or African American
    		 3 6 9
        White
    		 55 53 108
        More than one race
    		 0 0 0
        Unknown or Not Reported
    		 0 0 0
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    		 12 14 26
        Not Hispanic or Latino
    		 49 46 95
        Unknown or Not Reported
    		 0 0 0
    Area of Ellipsoid Zone Defect
    The area of ellipsoid zone defect was measured by en face spectral domain-optical coherence tomography. ITT included all participants who were randomized. Participants were analyzed according to the treatment to which they were assigned at the time of randomization regardless of the actual study drug the participant may have received during the participation in the study. Only participants with available data at Baseline were included.
    Units: mm^2
        arithmetic mean (standard deviation)
    		 4.31 ( 4.85 ) 3.94 ( 2.46 ) -

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Avacincaptad Pegol
    Reporting group description
    		 The participants received ACP 2 mg/eye on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: ACP 2 mg/eye o D14: ACP 2 mg/eye And the participants then received ACP 4 mg/eye monthly (Month 3 – Month 17) in the Maintenance Phase.

    Reporting group title
    Sham
    Reporting group description
    		 The participants received Sham on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: Sham o D14: Sham And the participants then received Sham monthly (Month 3 – Month 17) in the Maintenance Phase.

    Primary: Mean Rate of Change in the Area of Ellipsoid Zone Defect from Baseline through Month 18

    		 Close Top of page
    End point title
    		 Mean Rate of Change in the Area of Ellipsoid Zone Defect from Baseline through Month 18
    End point description
    The area of ellipsoid zone defect was measured by en face spectral domain-optical coherence tomography. Rate of change (slope) in the area of ellipsoid zone defect from Baseline through Month 18 was estimated using mixed model for repeated measures (MMRM). ITT included all participants who were randomized. Participants were analyzed according to the treatment to which they were assigned at the time of randomization regardless of the actual study drug the participant may have received during the participation in the study. Participants with either a non-missing baseline or non-missing post-baseline assessment were included.
    End point type
    Primary
    End point timeframe
    Baseline to Month 18
    End point values
    		 Avacincaptad Pegol Sham
    Number of subjects analysed
    61
    58
    Units: mm^2/18 months
        least squares mean (standard error)
    0.6383 ( 0.1113 )
    0.6644 ( 0.1081 )
    Statistical analysis title
    		 ACP versus (vs.) Sham
    Comparison groups
    Avacincaptad Pegol v Sham
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8669
    Method
    		 Mixed models analysis
    Parameter type
    		 difference in LS mean
    Point estimate
    -0.0261
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.3334
         upper limit
    		 0.2813
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.1551

    Secondary: Change in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters from Baseline at Month 18

    		 Close Top of page
    End point title
    		 Change in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters from Baseline at Month 18
    End point description
    BCVA in the study eye was assessed using ETDRS visual acuity testing chart. The ETDRS Visual Acuity Score (ETDRS letters) is calculated based on the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented increased visual functioning. A positive change from Baseline indicates an decrease in symptomology. Change in BCVA from Baseline at Month 18 was estimated using MMRM. ITT included all participants who were randomized. Participants were analyzed according to the treatment to which they were assigned at the time of randomization regardless of the actual study drug the participant may have received during the participation in the study. Participants with a non-missing baseline and at least one non-missing post-baseline assessment were included.
    End point type
    Secondary
    End point timeframe
    Baseline and Month 18
    End point values
    		 Avacincaptad Pegol Sham
    Number of subjects analysed
    61
    58
    Units: ETDRS letters
        least squares mean (standard error)
    -0.1326 ( 1.2080 )
    -1.3358 ( 1.1622 )
    Statistical analysis title
    		 ACP vs. Sham
    Comparison groups
    Avacincaptad Pegol v Sham
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.4745
    Method
    		 Mixed models analysis
    Parameter type
    		 difference in LS mean
    Point estimate
    1.2032
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -2.1196
         upper limit
    		 4.5259
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.6765

    Secondary: Change in Photopic or Mesopic Macular Sensitivity Measured by Microperimetry from Baseline at Month 18

    		 Close Top of page
    End point title
    		 Change in Photopic or Mesopic Macular Sensitivity Measured by Microperimetry from Baseline at Month 18
    End point description
    Photopic macular sensitivity or mesopic macular sensitivity were measured by microperimetry. Participants either had a photopic or mesopic measurement taken depending on the resources available at their site. Researchers were provided with one measurement regardless of the type of lighting conditions the assessment was conducted in. A higher score represented an increased retinal sensitivity. A positive change from Baseline indicates an improvement in symptomology. Change in Photopic or Mesopic Macular Sensitivity from Baseline at Month 18 was estimated using MMRM. ITT included all participants who were randomized. Participants were analyzed according to the treatment to which they were assigned at the time of randomization regardless of the actual study drug the participant may have received during the participation in the study. Participants with a non-missing baseline and at least one non-missing post-baseline assessment were included.
    End point type
    Secondary
    End point timeframe
    Baseline and Month 18
    End point values
    		 Avacincaptad Pegol Sham
    Number of subjects analysed
    20
    19
    Units: dB
        least squares mean (standard error)
    -1.1604 ( 0.7964 )
    -1.9184 ( 0.8128 )
    Statistical analysis title
    		 ACP vs. Sham
    Comparison groups
    Avacincaptad Pegol v Sham
    Number of subjects included in analysis
    39
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.5145
    Method
    		 Mixed models analysis
    Parameter type
    		 difference in LS mean
    Point estimate
    0.758
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.592
         upper limit
    		 3.108
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.1487

    Secondary: Number of Participants with Adverse Events (AEs)

    		 Close Top of page
    End point title
    		 Number of Participants with Adverse Events (AEs)
    End point description
    An AE is defined as any untoward medical occurrence in a participant including unfavorable and unintended signs, symptoms or disease temporally associated with the use of a medicinal product and which does not necessarily have to have a causal relationship to this treatment. AEs include illnesses with onset during the trial, or exacerbations of pre-existing illnesses. Exacerbation of pre-existing illness is defined as a significant increase in the severity of the illness as compared to the start of the trial and was considered when a participant requires new or additional treatment for that illness. Lack of or insufficient clinical response or efficacy was not recorded as an AE. Safety Analysis Set (SAF) included all participants who received at least one dose of study drug. Participants were analyzed in the ACP group if they ever received ACP at any time during the study. Participants that received Sham and never received ACP were analyzed in the Sham group.
    End point type
    Secondary
    End point timeframe
    Up to 18 months
    End point values
    		 Avacincaptad Pegol Sham
    Number of subjects analysed
    61
    58
    Units: Participants
    53
    45
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose up to 18 months
    Adverse event reporting additional description
    SAF included all participants who received at least one dose of study drug.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    v24.1
    Reporting groups
    Reporting group title
    Sham
    Reporting group description
    		 The participants received Sham on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: Sham o D14: Sham And the participants then received Sham monthly (Month 3 – Month 17) in the Maintenance Phase.

    Reporting group title
    Avacincaptad Pegol
    Reporting group description
    		 The participants received ACP 2 mg/eye on Day 1, Month 1, and Month 2 in the following sequence, 14 days apart in the Induction Phase: o D0: ACP 2 mg/eye o D14: ACP 2 mg/eye And the participants then received ACP 4 mg/eye monthly (Month 3 – Month 17) in the Maintenance Phase.

    Serious adverse events
    		 Sham Avacincaptad Pegol
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 58 (3.45%)
    3 / 61 (4.92%)
         number of deaths (all causes)
    0
    1
         number of deaths resulting from adverse events
    0
    1
    Injury, poisoning and procedural complications
    Ligament rupture
         subjects affected / exposed
    1 / 58 (1.72%)
    0 / 61 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 58 (0.00%)
    1 / 61 (1.64%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Eye disorders
    Endophthalmitis
         subjects affected / exposed
    0 / 58 (0.00%)
    1 / 61 (1.64%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotony of eye
         subjects affected / exposed
    0 / 58 (0.00%)
    1 / 61 (1.64%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhegmatogenous retinal detachment
         subjects affected / exposed
    0 / 58 (0.00%)
    1 / 61 (1.64%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Sepsis
         subjects affected / exposed
    1 / 58 (1.72%)
    0 / 61 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Sham Avacincaptad Pegol
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    41 / 58 (70.69%)
    47 / 61 (77.05%)
    Investigations
    Intraocular pressure increased
         subjects affected / exposed
    0 / 58 (0.00%)
    10 / 61 (16.39%)
         occurrences all number
    0
    58
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    4 / 58 (6.90%)
    2 / 61 (3.28%)
         occurrences all number
    4
    2
    Ligament sprain
         subjects affected / exposed
    4 / 58 (6.90%)
    1 / 61 (1.64%)
         occurrences all number
    4
    1
    Vascular disorders
    Hypertension
         subjects affected / exposed
    3 / 58 (5.17%)
    1 / 61 (1.64%)
         occurrences all number
    3
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    9 / 58 (15.52%)
    9 / 61 (14.75%)
         occurrences all number
    30
    30
    Eye disorders
    Dry eye
         subjects affected / exposed
    5 / 58 (8.62%)
    4 / 61 (6.56%)
         occurrences all number
    5
    4
    Conjunctival oedema
         subjects affected / exposed
    0 / 58 (0.00%)
    5 / 61 (8.20%)
         occurrences all number
    0
    26
    Eye pain
         subjects affected / exposed
    7 / 58 (12.07%)
    9 / 61 (14.75%)
         occurrences all number
    10
    24
    Ocular hyperaemia
         subjects affected / exposed
    1 / 58 (1.72%)
    4 / 61 (6.56%)
         occurrences all number
    1
    6
    Punctate keratitis
         subjects affected / exposed
    4 / 58 (6.90%)
    8 / 61 (13.11%)
         occurrences all number
    6
    13
    Seasonal allergy
         subjects affected / exposed
    3 / 58 (5.17%)
    1 / 61 (1.64%)
         occurrences all number
    4
    1
    Vision blurred
         subjects affected / exposed
    3 / 58 (5.17%)
    4 / 61 (6.56%)
         occurrences all number
    3
    4
    Vitreous detachment
         subjects affected / exposed
    1 / 58 (1.72%)
    4 / 61 (6.56%)
         occurrences all number
    1
    4
    Vitreous floaters
         subjects affected / exposed
    1 / 58 (1.72%)
    7 / 61 (11.48%)
         occurrences all number
    1
    9
    Conjunctival haemorrhage
         subjects affected / exposed
    10 / 58 (17.24%)
    31 / 61 (50.82%)
         occurrences all number
    21
    140
    Conjunctival hyperaemia
         subjects affected / exposed
    5 / 58 (8.62%)
    6 / 61 (9.84%)
         occurrences all number
    13
    9
    Eye irritation
         subjects affected / exposed
    5 / 58 (8.62%)
    8 / 61 (13.11%)
         occurrences all number
    15
    12
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 58 (0.00%)
    5 / 61 (8.20%)
         occurrences all number
    0
    6
    Infections and infestations
    COVID-19
         subjects affected / exposed
    3 / 58 (5.17%)
    1 / 61 (1.64%)
         occurrences all number
    3
    1
    Influenza
         subjects affected / exposed
    5 / 58 (8.62%)
    0 / 61 (0.00%)
         occurrences all number
    5
    0
    Nasopharyngitis
         subjects affected / exposed
    11 / 58 (18.97%)
    12 / 61 (19.67%)
         occurrences all number
    19
    13
    Sinusitis
         subjects affected / exposed
    3 / 58 (5.17%)
    3 / 61 (4.92%)
         occurrences all number
    3
    3
    Urinary tract infection
         subjects affected / exposed
    4 / 58 (6.90%)
    6 / 61 (9.84%)
         occurrences all number
    4
    8

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Mar 27 07:43:31 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA